Company Interview / Cleo Diagnostics' big strides against ovarian cancer

Andrew Stephens from Cleo Diagnostics (ASX:COV) shares that the company has signed a collaboration agreement with University College London to advance test development for ovarian cancer. This partnership grants access to over 2000 high-quality blood samples, enhancing Cleo's early cancer detection technology.

Andrew highlights the significance of utilising samples from the UK's largest ovarian cancer screening study, involving over 200,000 women. This independent validation accelerates Cleo's development, offering strategic and financial value while supporting future regulatory submissions, including to the FDA and TGA.

Additionally, Cleo Diagnostics (ASX:COV) receives a financial boost with an $800,000 cash refund through the Australian government's R&D tax incentive scheme. Andrew states this strengthens Cleo's financial position, ensuring sufficient funds to complete ongoing and planned studies, expediting market entry and potential investor returns.